Reading AXGN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AXGN free→Reading AXGN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AXGN free→QuarterlyIQ Insights · AXGN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or under the Exchange Act, unless the Company expressly sets forth in such future filing that such in…
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or under the Exchange Act, unless the Company expressly sets forth in such future filing that such in…
Other Events. Offering Press Releases On January 21, 2026, the Company issued a press release announcing the commencement of the Offering and also issued a press release announcing the pricing of the Offering. A copy of each press release is attached as Exhibit 99.1 and 99.2, respectively, to this Current Report on Form 8-K. Expected Payoff of Credit Facility The Company entered into a Term Loan Agreement, dated June 30, 2020 (as amended from time to time, the “Credit Facility”), with Oberlan…
Entry into a Material Definitive Agreement. On January 21, 2026, Axogen, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Wells Fargo Securities, LLC and Mizuho Securities USA LLC, as representatives of the underwriters (the “Underwriters”). Pursuant to the terms and conditions of the Underwriting Agreement, the Company agreed to sell 4,000,000 shares of its common stock, $0.01 par value per share (“Common Stock”), at a public offering price of $…
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or under the Exchange Act, unless the Company expressly sets forth in such future filing that such in…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On December 3, 2025 , the Compensation Committee of the Board of Directors of Axogen, Inc. (the “Company”) approved amendments to the compensation arrangements for Lindsey Hartley, the Company’s Chief Financial Officer. Effective January 1, 2026, Ms. Hartley’s: • annual base salary will increase by 7%, and • target bonus opportunity under the Compan…
Other Events On December 3, 2025 , the Company announced it received FDA approval of its Biologics License Application for Avance ® (acellular nerve allograft-arwx). Continued approval for these indications depends on verification and description of clinical benefit in confirmatory studies. The indications for sensory nerve discontinuities >25 mm and for mixed and motor nerve discontinuities were approved under FDA’s Accelerated Approval pathway based on the effect on static two-point discrim…
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or under the Exchange Act, unless the Company expressly sets forth in such future filing that such in…
Regulation FD Disclosure On August 22, 2025, Axogen, Inc. (the “Company”) received a communication from the U.S. Food and Drug Administration (the “FDA”) stating that the Company’s recent submission of facility and manufacturing information, provided in response to an FDA information request, constitutes a Major Amendment to the Company’s Biologics License Application (“BLA”) for Avance ® Nerve Graft. The FDA indicated that the submission contained a substantial amount of new manufacturing or…
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or under the Exchange Act, unless the Company expressly sets forth in such future filing that such in…
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or under the Exchange Act, unless the Company expressly sets forth in such future filing that such in…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Directors Departure of Nir Naor Nir Naor, the Chief Financial Officer (the “CFO”) of the Company, will step down from his role effective May 11, 2025 , but will remain employed by the Company in an advisory capacity following his departure from the CFO position. Pursuant to the terms of the Transition and Separation Agreement, dated May 7, 2025, between the…
Regulation FD Disclosure. On April 2, 2025, President Donald J. Trump announced a plan that would implement a broad range of tariffs on goods imported into the United States. Axogen, Inc. (the "Company") anticipates minimal impact from these tariffs, as well as from any retaliatory actions taken by other countries, on its current financials and underlying business model. The vast majority of the Company's sales are domestic, as is the manufacturing of its products. The costs associated with i…
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into any future filings by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or under the Exchange Act, unless the Company expressly sets forth in such future filing that suc…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.